DE60025016D1 - Fusionsprotein aus HPV-L1 und einem Peptid, das ein VLP bilden kann und als Vehikel zum EInschleusen eines Peptids in eine Zelle dienen kann, sowie dessen medizinische Verwendungen - Google Patents

Fusionsprotein aus HPV-L1 und einem Peptid, das ein VLP bilden kann und als Vehikel zum EInschleusen eines Peptids in eine Zelle dienen kann, sowie dessen medizinische Verwendungen

Info

Publication number
DE60025016D1
DE60025016D1 DE60025016T DE60025016T DE60025016D1 DE 60025016 D1 DE60025016 D1 DE 60025016D1 DE 60025016 T DE60025016 T DE 60025016T DE 60025016 T DE60025016 T DE 60025016T DE 60025016 D1 DE60025016 D1 DE 60025016D1
Authority
DE
Germany
Prior art keywords
peptide
hpv
carrier
well
vlp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60025016T
Other languages
English (en)
Inventor
Per Antonsson
Karin Kristensson
Marie Wallen-Oehman
Joakim Dillner
Peter Lando
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Active Biotech AB
Original Assignee
Active Biotech AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Active Biotech AB filed Critical Active Biotech AB
Application granted granted Critical
Publication of DE60025016D1 publication Critical patent/DE60025016D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Otolaryngology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Tropical Medicine & Parasitology (AREA)
DE60025016T 1999-09-30 2000-09-19 Fusionsprotein aus HPV-L1 und einem Peptid, das ein VLP bilden kann und als Vehikel zum EInschleusen eines Peptids in eine Zelle dienen kann, sowie dessen medizinische Verwendungen Expired - Lifetime DE60025016D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9903534A SE514982C2 (sv) 1999-09-30 1999-09-30 Bärare innehållande ett huvudkapsidprotein L1 från humant papillomavirus samt dess användning
PCT/SE2000/001808 WO2001023422A1 (en) 1999-09-30 2000-09-19 Vaccine

Publications (1)

Publication Number Publication Date
DE60025016D1 true DE60025016D1 (de) 2006-01-26

Family

ID=20417209

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60025016T Expired - Lifetime DE60025016D1 (de) 1999-09-30 2000-09-19 Fusionsprotein aus HPV-L1 und einem Peptid, das ein VLP bilden kann und als Vehikel zum EInschleusen eines Peptids in eine Zelle dienen kann, sowie dessen medizinische Verwendungen

Country Status (25)

Country Link
EP (1) EP1222200B1 (de)
JP (1) JP2003510064A (de)
KR (1) KR20020047195A (de)
CN (1) CN1373771A (de)
AT (1) ATE313559T1 (de)
AU (1) AU771481B2 (de)
BR (1) BR0014666A (de)
CA (1) CA2384723A1 (de)
CZ (1) CZ20021023A3 (de)
DE (1) DE60025016D1 (de)
EE (1) EE200200157A (de)
HR (1) HRP20020092A2 (de)
HU (1) HUP0202770A3 (de)
IL (1) IL148741A0 (de)
MX (1) MXPA02003328A (de)
NO (1) NO20020615L (de)
NZ (1) NZ516725A (de)
PL (1) PL355012A1 (de)
RU (1) RU2002111554A (de)
SE (1) SE514982C2 (de)
SK (1) SK4222002A3 (de)
TR (1) TR200200802T2 (de)
WO (1) WO2001023422A1 (de)
YU (1) YU22202A (de)
ZA (1) ZA200200886B (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY139500A (en) * 2003-11-12 2009-10-30 Merck Sharp & Dohme Optimized expression of hpv 58 l1 in yeast
ATE466022T1 (de) * 2004-03-24 2010-05-15 Merck Sharp & Dohme Optimierte expression von hpv-52-l1 in hefe
DE102004036913A1 (de) * 2004-07-16 2006-02-09 Responsif Gmbh Verwendung von Pentameren zur Herstellung eines Medikaments
CN1796403B (zh) * 2004-12-22 2010-04-28 三峡大学 用于多型人乳头瘤病毒感染防治的多肽和疫苗
CN100392084C (zh) * 2006-03-13 2008-06-04 曾毅 含密码子优化型hpv16l1基因的重组腺病毒
CN101914139B (zh) * 2010-07-16 2012-11-21 四川大学 人类乳头瘤病毒(hpv)衣壳蛋白l1多肽及其制备与应用
MY202196A (en) 2017-06-23 2024-04-16 Verimmune Inc Chimeric virus-like particles and uses thereof as antigen-specific redirectors of immune responses
WO2020139978A1 (en) 2018-12-27 2020-07-02 Verimmune Llc Conjugated virus-like particles and uses thereof as anti-tumor immune redirectors
US20220152166A1 (en) * 2019-02-08 2022-05-19 Rensselaer Polytechnic Institute A contraceptive vaccine based on the sperm-associated protein catsper
AU2021364548A1 (en) 2020-10-19 2023-06-08 Verimmune Inc. Virus-inspired compositions and methods of redirecting preexisting immune responses using the same for treatment of cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2264563T3 (es) * 1994-10-07 2007-01-01 Loyola University Of Chicago Particulas semejantes al virus del papiloma, proteinas de fusion y procedimiento para su preparacion.
FR2768749A1 (fr) * 1997-09-22 1999-03-26 Inst Nat Sante Rech Med Virus artificiels derives de papillomavirus, et leurs utilisations, notamment en therapie genique
DE19812941A1 (de) * 1998-03-24 1999-10-07 Medigene Ag Arzneimittel zur Vermeidung oder Behandlung von Papillomavirusspezifischem Tumor

Also Published As

Publication number Publication date
EP1222200A1 (de) 2002-07-17
BR0014666A (pt) 2002-06-18
NZ516725A (en) 2003-03-28
EE200200157A (et) 2003-04-15
NO20020615L (no) 2002-05-29
SE514982C2 (sv) 2001-05-28
WO2001023422A1 (en) 2001-04-05
MXPA02003328A (es) 2004-09-10
IL148741A0 (en) 2002-09-12
ZA200200886B (en) 2003-03-26
CN1373771A (zh) 2002-10-09
JP2003510064A (ja) 2003-03-18
AU7695100A (en) 2001-04-30
YU22202A (sh) 2005-06-10
EP1222200B1 (de) 2005-12-21
HRP20020092A2 (en) 2003-06-30
ATE313559T1 (de) 2006-01-15
TR200200802T2 (tr) 2002-09-23
HUP0202770A2 (hu) 2002-12-28
RU2002111554A (ru) 2004-03-27
CA2384723A1 (en) 2001-04-05
CZ20021023A3 (cs) 2002-07-17
AU771481B2 (en) 2004-03-25
PL355012A1 (en) 2004-03-22
SE9903534D0 (sv) 1999-09-30
NO20020615D0 (no) 2002-02-08
KR20020047195A (ko) 2002-06-21
HUP0202770A3 (en) 2004-07-28
SK4222002A3 (en) 2002-10-08
SE9903534L (sv) 2001-03-31

Similar Documents

Publication Publication Date Title
TW200519203A (en) Optimized expression of HPV 58 L1 in yeast
ES2643554T3 (es) Proceso y sistema para obtener neurotoxina botulínica
JP2012010713A (ja) パピローマウイルス様粒子、融合タンパク質並びにそれらの製造方法
DE60025016D1 (de) Fusionsprotein aus HPV-L1 und einem Peptid, das ein VLP bilden kann und als Vehikel zum EInschleusen eines Peptids in eine Zelle dienen kann, sowie dessen medizinische Verwendungen
DE69731289D1 (de) Immunglobulinähnliche domäne mit erhöhten halbwertszeiten
JPS59500498A (ja) １ａ型乳頭腫ウイルスゲノムのＬ１及びＬ２領域由来のＤＮＡ断片
BR0210599A (pt) Uso de monóxido de carbono, método para manutenção de uma célula animal in vitro, artigo de manufatura, bem como meio celular estéril
BR9913026A (pt) Processo de purificação de partìculas semelhantes a vìrus (vlps) de papilomavìrus recombinante, e, processo de preparação de um produto de vlp de papilomavìrus humano purificado adequado para uso em uma vacina para humano
AR045804A1 (es) Expresion optimizada de l1 del vph45 en levaduras
DK1629088T3 (da) Varianter af prostatastamcelleantigen (psca) og undersekvenser deraf
CA2283462A1 (en) Vectors having enhanced expression and methods of making and uses thereof
AR048191A1 (es) Expresion optimizada de hpv 52 l1 en levaduras
EP1037917A4 (de) Rekombinante nodavirus-zusammensetzungen und verfahren
UY24367A1 (es) Vacunas contra tumores y procedimiento para su produccion
CN101570571B (zh) 截短的人乳头瘤病毒18型l1蛋白
KR930702522A (ko) 인체의 투명층 단백질 제트피 3 (zp3)
Horváth et al. Toward the development of a synthetic group a streptococcal vaccine of high purity and broad protective coverage
AR004567A1 (es) Metodos para detectar la infeccion de t.cruzi, en una muestra biologica, un vector de expresion recombinante, un microorganismo modificado, un kit de diagnostico, una composicion farmaceutica, el uso de la composicion farmaceutica para la preparacion de un medicamento para estimular la produccion de anticuerpos que se liguen a t. cruzi.
DE60326449D1 (de) Chimere human papilloma virus 16 l1 proteine, welche ein l2 peptid enthalten, damit hergestellte virus-ähnliche partikel und methode zur herstellung der partikel
DK1334197T3 (da) Gær-afledt vaccine mod IPNV
BRPI0410655A (pt) composição farmacêutica, método de tratar ou prevenir uma infecção pelo vìrus da raiva em um indivìduo em necessidade deste tratamento, vetor de expressão de rhabdovìrus recombinante, célula hospedeira de mamìfero, método de produzir uma anticorpo recombinante humano neutralizante do vìrus da raiva em uma célula de mamìfero, e, uso de uma combinação
DK1287142T3 (da) Nukleinsyremolekyle omfattende en for et SDF-1 gamma chemokin, en neuropeptid-præcursor eller mindst et neuropeptid kodende nukleinsyresekvens
MXPA03007002A (es) Factor estimulante de colonia de granulocitos (g-csf) modificado con inmunogenicidad reducida.
GB0028319D0 (en) Materials and methods relating to fusion proteins for inducing an immune response
Nakano et al. Regenerative Nanotechnology: Engineered Surfaces for Stem Cell Production

Legal Events

Date Code Title Description
8332 No legal effect for de